United States Chronic Obstructive Pulmonary Disease (COPD) Biologics Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The global chronic obstructive pulmonary disease (COPD) biologics market size reached US$ 604.70 million in 2024 is expected to reach US$ 1,678.90 million by 2033, growing at a CAGR of 12.1% during the forecast period 2025-2033.

Key Development:

United States: Recent Industry Developments

✅ In July 2025, Merck announced a $10 billion acquisition of Verona Pharma, aiming to expand its cardiopulmonary portfolio and enhance access to Ohtuvayre for COPD patients.

✅ In September 2024, the U.S. FDA approved Dupixent (dupilumab) as the first-ever biologic medicine for patients with COPD. This marks a significant advancement in targeted therapy for COPD patients with an eosinophilic phenotype.

✅ In June 2024, Verona Pharma's Ohtuvayre (ensifentrine), a first-in-class inhaled therapy, received FDA approval for the maintenance treatment of COPD. This novel medication offers a new mechanism of action in over two decades.

Japan: Recent Industry Developments

✅ In July 2025, Japan's respiratory drugs market was projected to grow steadily, driven by advancements in COPD treatments and an aging population.

✅ In May 2025, AstraZeneca initiated the RESOLUTE Phase III trial to evaluate Fasenra (benralizumab) in COPD patients. This trial aims to assess the efficacy and safety of Fasenra in a new patient population.

✅ In March 2025, Japan's regulatory authorities approved Dupixent as the first-ever biologic medicine for patients with COPD, introducing a new treatment approach in the country.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/chronic-obstructive-pulmonary-disease-copd-biologics-market?sb

Recent Mergers and Acquisitions:

United States: Recent M&A Developments in COPD Biologics

✅ In July 2025, GSK entered into a significant partnership with China's Hengrui Pharma, valued at $12 billion, to enhance its COPD offerings. This collaboration focuses on advancing 12 programs related to respiratory diseases, aligning with GSK's strategy to expand its presence in the COPD market.

Japan: Recent M&A Developments in COPD Biologics

✅ In July 2025, Japan's regulatory authorities approved Dupixent (dupilumab) as the first-ever biologic medicine for patients with COPD. This approval introduces a new treatment approach for COPD in Japan, marking the first in over a decade.

Key Players:

=> Sanofi, Regeneron Pharmaceuticals, and GSK are leading players, with their innovative biologic therapies like Dupilumab and Mepolizumab.

Growth Forecast Projected:

The Global Chronic Obstructive Pulmonary Disease (COPD) Biologics Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2033. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Chronic Obstructive Pulmonary Disease (COPD) Biologics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=chronic-obstructive-pulmonary-disease-copd-biologics-market

Key Segments:

➥ By Drug Class: Dupilumab, Mepolizumab

➥ By Route of Administration: Subcutaneous

➥ By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Regional Analysis for Chronic Obstructive Pulmonary Disease (COPD) Biologics Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Chronic Obstructive Pulmonary Disease (COPD) Biologics producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Chronic Obstructive Pulmonary Disease (COPD) Biologics revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/chronic-obstructive-pulmonary-disease-copd-biologics-market?sb

FAQ

What is the current size of the Chronic Obstructive Pulmonary Disease (COPD) Biologics Market?

A: In 2024, the Chronic Obstructive Pulmonary Disease (COPD) Biologics Market was valued at US$ 604.70 million, reflecting its strong industry presence.

Q2: How large is the Chronic Obstructive Pulmonary Disease (COPD) Biologics Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Chronic Obstructive Pulmonary Disease (COPD) Biologics Market will grow to around US$ 1,678.90 million , demonstrating significant expansion.

Q3: What is the growth rate of the Chronic Obstructive Pulmonary Disease (COPD) Biologics Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 12.1% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us
-

Company
Name: DataM Intelligence

Contact Person: Sai Kiran

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.